Myung In Pharmaceutical LTD. (KRX:317450)
South Korea flag South Korea · Delayed Price · Currency is KRW
66,000
+3,600 (5.77%)
At close: Feb 4, 2026

KRX:317450 Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
225,20932,89734,44918,25152,96770,504
Short-Term Investments
250,138227,399153,080124,43467,786183
Cash & Short-Term Investments
475,347260,296187,529142,686120,75370,687
Cash Growth
153.48%38.80%31.43%18.16%70.83%12.19%
Accounts Receivable
62,66260,77158,14756,78356,68857,571
Other Receivables
3,8073,4923,7112,7102,1382,231
Receivables
66,63064,43362,02059,64659,03360,068
Inventory
62,66060,34356,27747,88046,73244,057
Prepaid Expenses
352.31510.71434.13533.52243.22253.98
Other Current Assets
1,154225.491,32972.68176.4972.08
Total Current Assets
606,144385,809307,589250,818226,938175,138
Property, Plant & Equipment
110,81199,25999,309103,706110,187151,957
Long-Term Investments
9,64010,78328,60824,2426,804889.1
Other Intangible Assets
5,431713.02710.9711.01711.691,052
Long-Term Accounts Receivable
1,9042,2312,0392,3002,5452,364
Long-Term Deferred Tax Assets
111.86---4.514.35
Other Long-Term Assets
82,23082,71783,11989,52882,34451,546
Total Assets
816,508581,692521,590471,556429,760383,032
Accounts Payable
6,1568,2982,3972,1292,2452,008
Accrued Expenses
1,2901,3271,4251,2962,2901,613
Current Portion of Leases
1,5441,5281,7271,7391,3291,412
Current Income Taxes Payable
8,62012,38912,94911,47213,4949,157
Other Current Liabilities
24,85921,05920,68618,45820,37422,829
Total Current Liabilities
42,48944,60239,18435,09339,73237,019
Long-Term Leases
152.361,1722,1603,2064,2815,534
Long-Term Unearned Revenue
15.8970.23115.85161.47--
Pension & Post-Retirement Benefits
1,313---668.612,084
Long-Term Deferred Tax Liabilities
-1,4395,3276,6846,6056,637
Other Long-Term Liabilities
833.912,5892,4892,4322,3821,335
Total Liabilities
44,80449,87149,27647,57753,66852,609
Common Stock
7,3005,6005,6005,6005,6005,600
Retained Earnings
580,249533,269471,701421,245373,297327,627
Comprehensive Income & Other
-7,928-7,049-4,988-2,866-2,805-2,805
Shareholders' Equity
771,704531,821472,314423,979376,092330,423
Total Liabilities & Equity
816,508581,692521,590471,556429,760383,032
Total Debt
1,6962,7003,8874,9455,6096,946
Net Cash (Debt)
473,651257,596183,642137,740115,14363,741
Net Cash Growth
157.92%40.27%33.32%19.63%80.64%2.87%
Net Cash Per Share
42043.3622999.6316396.6212298.2510280.655691.17
Filing Date Shares Outstanding
11.4611.211.211.211.211.2
Total Common Shares Outstanding
11.4611.211.211.211.211.2
Working Capital
563,655341,207268,406215,724187,206138,119
Book Value Per Share
67358.4947483.9842170.8937855.2833579.6429502.05
Tangible Book Value
766,273531,108471,603423,268375,380329,371
Tangible Book Value Per Share
66884.4747420.3142107.4137791.8033516.1029408.15
Land
39,46739,46739,08937,09836,95567,520
Buildings
59,27359,17959,29159,02058,92362,627
Machinery
99,15195,86590,30487,40385,97083,833
Construction In Progress
21,7845,2361,374258.5286.44284
Source: S&P Global Market Intelligence. Standard template. Financial Sources.